-
Mashup Score: 21Top advances of the year: Melanoma - 21 day(s) ago
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 21Top advances of the year: Melanoma - 21 day(s) ago
Cancer is an international interdisciplinary journal publishing articles on the latest clinical cancer research findings, spanning the breadth of oncology disciplines.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11
The American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) are calling on manufacturers of diagnostics and therapeutics to adopt therapeutic group labeling to
Source: society.asco.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34
Background Intratumorally delivered immunotherapies have the potential to favorably alter the local tumor microenvironment and may stimulate systemic host immunity, offering an alternative or adjunct to other local and systemic treatments. Despite their potential, these therapies have had limited success in late-phase trials for advanced cancer resulting in few formal approvals. The Society for Immunotherapy of Cancer (SITC) convened a panel of experts to determine how to design clinical trials with the greatest chance of demonstrating the benefits of intratumoral immunotherapy for patients with cancers across all stages of pathogenesis. Methods An Intratumoral Immunotherapy Clinical Trials Expert Panel composed of international key stakeholders from academia and industry was assembled. A multiple choice/free response survey was distributed to the panel, and the results of this survey were discussed during a half-day consensus meeting. Key discussion points are summarized in the follow
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 41
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Pembrolizumab adjuvant therapy was shown to significantly improve recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) in patients with resected stage IIB or IIC melanoma in earlier analyses of the randomized, double-blind, phase III KEYNOTE-716 study (ClinicalTrials.gov identifier: NCT03553836). We report results of the protocol-specified final analysis of DMFS for KEYNOTE-716. Overall, 976 patients were randomly allocated to pembrolizumab (n = 487) or placebo (n = 489). As of January 4, 2023, median follow-up was 39.4 months (range, 26.0-51.4 mont
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
3 year update for KN716 now online @JCO_ASCO. Foundational data for adjuvant #melanoma emphasizing patients with stage IIB/C dz are at high risk & anti-PD1 is highly effective to prevent recurrence. Next step - biomarker work to optimize patient selection! https://t.co/cI55QkTwmE https://t.co/XmWMWAHr1i
-
-
Mashup Score: 27Source: link.springer.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 59Deep whole-genome analysis of 494 hepatocellular carcinomas - 3 month(s) ago
Nature – The Chinese Liver Cancer Atlas project depicts a panoramic genomic landscape of hepatocellular carcinoma, covering candidate coding and non-coding drivers, mutational signatures,…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5Revolution in the next KRAS battleground - 3 month(s) ago
With Revolution Medicines initiating dosing in the first-in-human study of its KRAS G12D inhibitor RMC-9805, the industry pipeline now comprises six clinical-stage projects with this modality. If the KRAS G12C space, now featuring the approved drugs Lumakras from Amgen and Krazati from Mirati, fast became crowded, then that targeting KRAS G12D-driven tumours might follow suit, given that G12D is…
Source: www.oncologypipeline.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity - 4 month(s) ago
Nature Communications – Recognition of tumour antigen induces dendritic cell activation and migration to the lymph node. Here, the authors use photoconvertible mice to demonstrate that some…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 19
Abstract. The field of oncology has been transformed by immune checkpoint inhibitors (ICI) and other immune-based agents, however many patients do not receive a durable benefit. While biomarker assessments from pivotal ICI trials have uncovered certain mechanisms of resistance, results thus far have only scraped the surface. Mechanisms of resistance are as complex as the tumor microenvironment (TME) itself, and the development of effective therapeutic strategies will only be possible by building accurate models of the tumor-immune interface. With advancement of multi-omic technologies, high-resolution characterization of the TME is now possible. In addition to sequencing of bulk tumor, single-cell transcriptomic, proteomic, and epigenomic data as well as T cell receptor profiling can now be simultaneously measured and compared between responders and non-responders to ICI. Spatial sequencing and imaging platforms have further expanded the dimensionality of existing technologies. Rapid a
Source: aacrjournals.orgCategories: General Medicine News, Hem/OncsTweet-
Congrats @RyanAugustinMD @wesleylcai & field-leading comp bio collaborator @ImmunoTiil @RiyueSunnyBao on overview of multi-dimensional biomarker, omics & translational investigations to adv combo #immunotherapy. Field moving fast so get wise or get lost! https://t.co/sNVXRa4sPv https://t.co/a6UAiWSpZO
-
Top advances of the year #Melanoma! Great work @AdnanKhattakOnc on impact of TIL approval, novel strategies targeting PRAME, oncolytic virus as well as neo-/adjuvant strategies such as mRNA individualized neoAg therapy. Quick read to stay UTD! https://t.co/4aaPPh174w https://t.co/uzinJJmRfx